

Cell-Vive™ T cell CD Serum Substitute, GMP

Catalog# / Size	420506 / 50 mL
Other Names	Chemically-Defined (CD), Serum-free Human Serum Replacement
Description	<p>Cell-Vive™ T Cell CD Serum Substitute, GMP is specifically formulated to support PBMC-derived T cell expansion, resulting in equal or higher specific cell numbers compared to the use of human AB serum. It is a Chemically-Defined, serum-free formulation, prepared without human or other animal components, intended to be combined with the basal media of choice, such as IMDM. It is suitable for use in combination with several T cell activation methods and is able to support T cell populations (CD4, CD8) comparable to human AB serum. This GMP product is suggested for use in research and further manufacturing applications. The benefits of this serum substitute include:</p> <ul style="list-style-type: none"> Effective for maintaining CD4/CD8 balance. Maintains high cell viability, >90%, throughout cell culture. Minimizes safety risks associated with human AB serum. Improved lot-to-lot consistency over human AB serum. Saves time and costs required to qualify human AB serum

Product Details

Formulation	Chemically Defined, serum-free formulation
Storage & Handling	Store at -20°C to -5°C. Thaw overnight at 4°C. If necessary product can be kept at 4°C for up to two weeks.
Application	Cell Culture
Application Notes	<p>Complete cell Culture Media Preparation: Thaw Cell-Vive™ T cell CD Serum Substitute, GMP overnight at 4°C. The product can be stored at 4°C in the dark for up to 2 weeks post-thaw. Do not refreeze after initial thaw. The presence of cloudiness in the product after thaw is normal and relates to the high enrichment of the product. Make sure to mix product prior to use. Once the product is diluted into basal media, no cloudiness should be observed.</p> <p>Dilute Cell-Vive™ T cell CD Serum Substitute, GMP to 5% v/v in IMDM and 200 IU/mL of recombinant human IL-2 (BioLegend, Cat. No. 791906 or equivalent). Alternatively, the product can be used in combination with your basal media of choice and cytokines of interest. To determine optimal performance, a titration of the product under your desired cell culture setup may be required.</p> <p>Cell Culture Platform: Cell-Vive™ T cell CD Serum Substitute, GMP can be used with tissue culture plates, and flasks. If using a bag format, testing is recommended with the specific bag being used.</p> <p>Cell Activation methods: Cell-Vive™ T cell CD Serum Substitute, GMP can be used in combination with anti-human CD3 and CD28 antibodies in solution, plate-coated. Optimal values should be determined if using a different culture setup.</p> <p>For the protocols below, complete media refers to IMDM with 5% v/v Cell-Vive™ T cell CD Serum Substitute, GMP, and 200 IU/mL recombinant human IL-2 (BioLegend, Cat. No. 791906 or equivalent) for T cell culture.</p>

1. Coating plates with anti-human CD3 and CD28 antibodies

Add 1 µg/mL of anti-human CD3 (OKT3 clone, BioLegend, Cat. No. 317326 or equivalent) and 1 µg/mL of anti-CD28 antibodies (CD28.2 clone, BioLegend, Cat. No. 302934 or equivalent) to PBS. Add solution to the vessel, at recommended volume (table below). Incubate for 2 hrs at 37°C in a tissue culture incubator (or overnight at 4°C, preventing evaporation with Parafilm®). Aspirate solution and wash twice with 1 volume of PBS. Wells are ready to be used. Do not let wells dry.

TABLE 1: Recommended volumes of coating solution composed of anti-human CD3 and CD28 antibodies.

Vessel	Recommended volume
--------	--------------------

12- well plate	0.75 mL
6- well plate	2 mL
T25 flask	5 mL
T75 flask	15 mL

2. Soluble antibodies

Add 10 µg/mL of anti-human CD3 (OKT3 clone, BioLegend, Cat. No. 317326 or equivalent) and 5 µg/mL of anti-CD28 antibodies (CD28.2 clone, BioLegend, Cat. No. 302934 or equivalent) to complete media.

PBMC-Derived T cell culture protocol:

1. Equilibrate appropriate amount of complete media at 37°C for 10-15 min.
2. Plate PBMC (fresh or frozen) at 1×10^6 cells/mL and incubate at 37°C and 5% CO₂.
3. Allow cells to get activated for 3-4 days.
4. At day 3-4, dissociate cell clumps by pipetting until a single cell solution is observed.
5. Determine cell density.
6. Dilute cell culture to 0.25 - 0.5 $\times 10^6$ cells/mL and incubate at 37°C and 5% CO₂.
7. Repeat steps 4-6 every 2 days.
8. Monitor cell culture to make sure confluency is not reached. Pending donor-to-donor variability exponential expansion may require more frequent feeding. Complete media has been shown to support up to 4×10^6 cells/mL without impact on cell viability and quality.
9. Follow with further processing and/or cell analysis.

Parafilm is a registered trademark of Bemis Company, Inc.

Disclaimer

GMP Serum Substitute. BioLegend products are manufactured in an ISO 13485:2016-certified facility following GMP compliant procedures to ensure the highest quality standards. For research or further manufacturing use only. Not for use in diagnostic or therapeutic procedures. Our processes include:


- Batch-to-batch consistency
- Material traceability
- Documented procedures
- Documented employee training
- Equipment maintenance and monitoring records
- Lot-specific certificates of analysis
- Quality audits per ISO 13485:2016
- QA review of released products

BioLegend GMP Serum Substitute products are manufactured and tested in accordance with USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and Ph. Eur. Chapter 5.2.12.

Antigen Details



Gene ID NA

Product Data



Cell-Vive™ T cell CD Serum Substitute (T CD SS) supports high PBMC-derived T cell expansion and preserves viability and CD4/CD8 balance at similar levels than hAB serum or an equivalent commercially available product (Competitor A). PBMC-derived T cells were activated with 1 µg/mL of Ultra-LEAF™ anti-human CD3 antibody (Cat. No. 317347), 1 µg/mL of Ultra-LEAF™ anti-human CD28 antibody (302943) in IMDM basal media supplemented with 200 IU/mL recombinant human IL-2 (Cat. No. 791908) and appropriate supplements. Cell expansion (A) and viability (B) were determined on day 4, 6, 8 and end of culture (day 11). Flow cytometry was used to determine

specific T cell populations, on day 11, by making use of anti-human CD4 (Cat. No. 317408) and anti-human CD8 (Cat. No. 344722) cell markers (C).



For research and further manufacturing use. Not for diagnostic or therapeutic procedures. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to reverse engineer functionally similar materials without written approval of BioLegend. By use of these products you accept the terms and conditions of any and all applicable [Limited Use Label Licenses](#). Unless otherwise indicated, these products are for research and further manufacturing use only and not intended for human or animal diagnostic or therapeutic use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587